99 studies found for:    autoinflammatory
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes:;   Familial Cold Autoinflammatory Syndrome;   Muckle Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: Canakinumab (ACZ885)
2 Withdrawn A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
Conditions: Muckle Wells Syndrome;   Autoinflammatory;   Behcet's Disease
Intervention: Drug: XOMA 052
3 Completed Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: ACZ885
4 Completed
Has Results
Interleukin-1 Trap to Treat Autoinflammatory Diseases
Conditions: Inflammation;   Familial Mediterranean Fever;   Still's Disease, Adult-Onset
Intervention: Drug: IL-1 Trap
5 Completed Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: canakinumab
6 Unknown  The Efficacy and Safety of ITF2357 in AIS
Conditions: Autoinflammatory Syndromes;   HIDS;   TRAPS;   Schnitzler's Syndrome
Intervention: Drug: ITF2357
7 Completed
Has Results
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: ACZ885
8 Recruiting Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases)
Conditions: Urticaria;   Arthropathy;   Lymphadenopathy;   Nervous System Anomalies
Intervention:
9 Completed
Has Results
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Conditions: Familial Cold Autoinflammatory Syndrome (FCAS);   Familial Cold Urticaria;   Muckle-Wells Syndrome (MWS);   Genetic Diseases, Inborn
Interventions: Drug: rilonacept 160 mg;   Drug: Placebo
10 Recruiting Phenomics in Autoimmune and Inflammatory Diseases
Conditions: Healthy Volunteer;   Rheumatoid Arthritis;   Ankylosing Spondylitis;   Systemic Lupus Erythematosus/Antiphospholipid Syndrome;   FMF;   Cryopyrin-Associated Periodic Syndromes /TNF-receptor Associated Periodic Syndrome;   Vasculitis;   Uveitis;   Myositis;   Crohn's Disease;   Ulcerative Rectocolitis;   Type 1 Diabetes;   Unclassified IAD Knee and/or Hip Arthritis, Muscular Dystrophy
Interventions: Other: 1: AID groups;   Other: 2: Control groups
11 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
12 Completed
Has Results
Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome
Condition: Muckle Wells Syndrome
Interventions: Drug: ACZ885;   Drug: Placebo
13 Available Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Conditions: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE);   Juvenile Dermatomyositis (JDM);   Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)
Intervention: Drug: Baricitinib
14 Recruiting Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
Condition: Still's Disease, Adult-Onset
Intervention: Biological: Tadekinig alfa (recombinant human IL-18 binding protein)
15 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
16 Completed The CARRA Registry
Conditions: Juvenile Idiopathic Arthritis;   Systemic Lupus Erythematosus;   Mixed Connective Tissue Disease;   Juvenile Ankylosing Spondylitis;   Juvenile Dermatomyositis;   Localized Scleroderma;   Systemic Sclerosis;   Vasculitis;   Sarcoid;   Fibromyalgia, Primary;   Auto-inflammatory Disease;   Idiopathic Uveitis Idiopathic
Intervention:
17 Completed Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Condition: DIRA
Intervention: Drug: Rilonacept
18 Completed
Has Results
Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
Condition: Familial Mediterranean Fever
Interventions: Drug: Rilonacept;   Drug: Placebo
19 Active, not recruiting Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers
Condition: Hereditary Periodic Fevers
Interventions: Drug: canakinumab;   Drug: Placebo
20 Recruiting Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Condition: Inherited Immune Deficiencies
Interventions: Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years